---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-115538"
form_type: "8-K"
ticker: "NVCT"
cik: "0001875558"
company_name: "Nuvectis Pharma, Inc."
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T11:21:11.320218+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Nuvectis reports Q3 2023 net loss of $5.9M; cash $22.1M; NXP800 orphan drug status

## Summary
- Cash and investments $22.1M at Sep 30, 2023, up from $20.0M at Dec 31, 2022.
- Net loss $5.9M for Q3 2023, unchanged YoY; R&D expenses $4.5M.
- Phase 1b study of NXP800 in platinum-resistant ARID1a-mutated ovarian cancer ongoing; preliminary data expected Q1 2024.
- NXP900 Phase 1a dose escalation initiated in advanced solid tumors; novel preclinical data presented.
- FDA granted NXP800 Orphan Drug Designation for cholangiocarcinoma.

## SEC filing metadata
- accession: 0001104659-23-115538
- form_type: 8-K
- ticker: NVCT
- cik: 0001875558
- company_name: Nuvectis Pharma, Inc.
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1875558/000110465923115538/0001104659-23-115538-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1875558/000110465923115538/tm2330113d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-115538
- JSON: https://secwatch.observer/filing/0001104659-23-115538.json
- Plain text: https://secwatch.observer/filing/0001104659-23-115538.txt

## Key facts
- Earnings Releases
  Nuvectis Pharma, Inc. reported financial results for Third Quarter 2023.
  - Period: Third Quarter 2023
  - Result: reported results
  source text: Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights
  evidence_url: https://www.sec.gov/Archives/edgar/data/1875558/000110465923115538/0001104659-23-115538-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.